GlassScriptPhysician profile
Darryl J Ballin
NPI 1922174192
$5,230.55
in general payments reported to CMS, 2019-2025
39 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,740 · 2020: $390 · 2021: $1,337 · 2022: $468 · 2023: $629 · 2024: $436 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Amgen INC. | $577.12 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $326.96 | 2021-2025 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $302.37 | 2019-2021 | |
| Intuitive Surgical, INC. | $260.89 | 2020-2022 | |
| Pfizer INC. | $219.72 | 2019-2025 | |
| Glaxosmithkline, LLC. | $189.07 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.29 | 2024-2025 | Jardiance |
| Abbott Laboratories | $165.25 | 2023 | Proclaim, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $143.76 | 2019-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $140.33 | 2019-2020 | |
| Novo Nordisk INC | $138.10 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $129.90 | 2019-2020 | |
| Lilly USA, LLC | $120.94 | 2019-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $113.62 | 2023-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Ballin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.